The United States Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for use as a standalone treatment for depression.

This approval allows the medication, which contains the active ingredient esketamine, to be administered under strict medical supervision when other therapies have failed.

Esketamine is chemically related to ketamine, a substance traditionally used as an anesthetic and also known for its recreational drug use.

The approval marks a significant development in treating major depressive disorder, particularly for patients who do not respond adequately to conventional antidepressants.

The administration of Spravato must occur in a certified medical setting, reflecting the requirement for close monitoring due to potential side effects.

Patients using the nasal spray are observed for at least two hours post-administration to manage any immediate adverse reactions that might occur.

Esketamine is categorized under treatment options for treatment-resistant depression, which affects a substantial portion of people diagnosed with significant depressive disorders worldwide.

The decision by the FDA was based on several clinical trials that demonstrated the efficacy of Spravato in improving depressive symptoms in patients who had not seen results from other antidepressant medications.

As mental health issues present a growing concern globally, the approval of esketamine nasal spray by the FDA provides a new avenue of hope for individuals battling severe forms of depression that are not responsive to existing treatment regimens.

Johnson & Johnson has indicated its commitment to ensuring Spravato is rolled out effectively under a REMS (Risk Evaluation and Mitigation Strategy) program, illustrating the company's dedication to patient safety and the responsible use of the medication.